{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:06:48Z","timestamp":1760854008990,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"International Aicardi-Gouti\u00e8res Syndrome Association (IAGSA), Pavia, Italy."},{"DOI":"10.13039\/100007218","name":"Association for Cancer Research","doi-asserted-by":"crossref","award":["IG-20699"],"award-info":[{"award-number":["IG-20699"]}],"id":[{"id":"10.13039\/100007218","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13346-018-0535-3","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T18:08:55Z","timestamp":1528135735000},"page":"1345-1354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation"],"prefix":"10.1007","volume":"8","author":[{"given":"Sebastiano","family":"La Maestra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Frosina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna T.","family":"Micale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"D\u2019Oria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvano","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Daga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Pulliero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Izzotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,4]]},"reference":[{"key":"535_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","volume":"20","author":"AM Krieg","year":"2002","unstructured":"Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709\u201360.","journal-title":"Annu Rev Immunol"},{"key":"535_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/intimm\/dxp044","volume":"21","author":"G Chikh","year":"2009","unstructured":"Chikh G, de Jong SD, Sekirov L, Raney SG, Kazem M, Wilson KD, et al. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int Immunol. 2009;21:757\u201367.","journal-title":"Int Immunol"},{"key":"535_CR3","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1200\/JCO.2010.32.8971","volume":"29","author":"V Hirsh","year":"2011","unstructured":"Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhardt WE, et al. Randomized phase III trial of paclitaxel\/carboplatin with or without PF-3512676 (Toll like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:2667\u201374.","journal-title":"J Clin Oncol"},{"key":"535_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/nat.2012.0340","volume":"22","author":"AM Krieg","year":"2012","unstructured":"Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 2012;22:77\u201389.","journal-title":"Nucleic Acid Ther"},{"key":"535_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/annonc\/mdr030","volume":"23","author":"C Manegold","year":"2012","unstructured":"Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JS, Blasinska-Morawiec M, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2012;23:72\u20137.","journal-title":"Ann Oncol"},{"key":"535_CR6","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.1016\/j.vaccine.2014.06.065","volume":"12","author":"J Scheiermann","year":"2014","unstructured":"Scheiermann J, Klinman DM. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine. 2014;12:6377\u201389.","journal-title":"Vaccine"},{"key":"535_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0952-7915(99)00048-5","volume":"12","author":"AM Krieg","year":"2000","unstructured":"Krieg AM. The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000;12:35\u201343.","journal-title":"Curr Opin Immunol"},{"key":"535_CR8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/(SICI)1521-4141(199904)29:04<1209::AID-IMMU1209>3.0.CO;2-J","volume":"29","author":"S Bendigs","year":"1999","unstructured":"Bendigs S, Salzer U. GB, Lipford H, Wagner H, Heeg K. CpG oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol. 1999;29:1209\u201318.","journal-title":"Eur J Immunol"},{"key":"535_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri3850","volume":"15","author":"YJ Crow","year":"2015","unstructured":"Crow YJ, Manel N. Aicardi-Gouti\u00e8res syndrome and the type I interferonopathies. Nat Rev Immunol. 2015;15:429\u201340.","journal-title":"Nat Rev Immunol"},{"key":"535_CR10","first-page":"957","volume":"430","author":"A Pulliero","year":"2013","unstructured":"Pulliero A, Marengo B, Longobardi M, Fazzi E, Orcesi S, Olivieri I, et al. Inhibition of the de-myelinating properties of Aicardi-Gouti\u00e9res Syndrome lymphocytes by cathepsin D silencing. Biochem, Biophys. Res Commun. 2013;430:957\u201362.","journal-title":"Res Commun"},{"key":"535_CR11","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.autrev.2012.08.012","volume":"12","author":"E Fazzi","year":"2013","unstructured":"Fazzi E, Cattalini M, Orcesi S, Tincani A, Andreoli L, Balottin U, et al. Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder? Autoimmun Rev. 2013;12:506\u20139.","journal-title":"Autoimmun Rev"},{"key":"535_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/ng1842","volume":"38","author":"YJ Crow","year":"2006","unstructured":"Crow YJ, Leitch A, Hayward BE, Garner A, Parmar R, Griffith E. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Gouti\u00e8res syndrome and mimic congenital viral brain infection. Nat Genet. 2006;38:910\u20136.","journal-title":"Nat Genet"},{"key":"535_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/bmb\/ldn049","volume":"89","author":"S Orcesi","year":"2009","unstructured":"Orcesi S, La Piana R, Fazzi E. Aicardi-goutieres syndrome. Br Med Bull. 2009;89:183\u2013201.","journal-title":"Br Med Bull"},{"key":"535_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.mrfmmm.2011.03.018","volume":"1","author":"A Pulliero","year":"2011","unstructured":"Pulliero A, Fazzi E, Cartiglia C, Orcesi S, Balottin U, Uggetti C. The Aicardi-Gouti\u00e8res syndrome. Molecular and clinical features of RNAse deficiency and microRNA overload. Mutat Res. 2011;1:99\u2013108.","journal-title":"Mutat Res"},{"key":"535_CR15","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/B978-0-444-59565-2.00031-9","volume":"113","author":"YJ Crow","year":"2013","unstructured":"Crow YJ. Aicardi-goutieres syndrome. Handb Clin Neurol. 2013;113:1629\u201335.","journal-title":"Handb Clin Neurol"},{"key":"535_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1750-3639.2008.00229.x","volume":"19","author":"A Izzotti","year":"2009","unstructured":"Izzotti A, Pulliero A, Orcesi S, Cartiglia C, Longobardi MG, Capra V, et al. Interferon-related transcriptome alterations in the cerebrospinal fluid cells of Aicardi-Gouti\u00e8res patients. Brain Pathol. 2009;19:650\u201360.","journal-title":"Brain Pathol"},{"key":"535_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/cei.12147","volume":"175","author":"R Behrendt","year":"2014","unstructured":"Behrendt R, Roers A. Mouse models for Aicardi-Gouti\u00e9res Syndrome provide clues to the molecular pathogenesis of systemic autoimmunity. Clin Exp Immunol. 2014;175:9\u201316.","journal-title":"Clin Exp Immunol"},{"key":"535_CR18","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1084\/jem.20120876","volume":"30","author":"B Hiller","year":"2012","unstructured":"Hiller B, Achleitner M, Glage S, Naumann R, Behrendt R, Roers A. Mammalian RNase H2 removes ribonucleotides from DNA to maintain genome integrity. J Exp Med. 2012;30:1419\u201326.","journal-title":"J Exp Med"},{"key":"535_CR19","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1128\/MCB.24.15.6719-6727.2004","volume":"24","author":"M Morita","year":"2004","unstructured":"Morita M, Stamp G, Robins P, Dulic A, Rosewell I, Hrivnak G, et al. Gene-targeted mice lacking the Trex1 (DNase III) 3'-->5' DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol. 2004;24:6719\u201327.","journal-title":"Mol Cell Biol"},{"key":"535_CR20","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1073\/pnas.1222878110","volume":"26","author":"J Seok","year":"2013","unstructured":"Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Inflammation XW. Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;26:3507\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"535_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12115","volume":"175","author":"YJ Crow","year":"2014","unstructured":"Crow YJ, Vanderver A, Orcesi S, Kuijpers TW, Rice GI. Therapies in Aicardi-Gouti\u00e8res syndrome. Clin Exp Immunol. 2014;175:1\u20138.","journal-title":"Clin Exp Immunol"},{"key":"535_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","volume":"30","author":"G Wiederrecht","year":"1993","unstructured":"Wiederrecht G, Lam E, Hung S, Martin M, Sigal N. The mechanism of action of FK-506 and cyclosporine. A Ann N Y Acad Sci. 1993;30:9\u201319.","journal-title":"A Ann N Y Acad Sci"},{"key":"535_CR23","doi-asserted-by":"publisher","first-page":"e41451","DOI":"10.1371\/journal.pone.0041451","volume":"7","author":"JM Reimer","year":"2012","unstructured":"Reimer JM, Karlsson KH, L\u00f6vgren-Bengtsson K, Magnusson SE, Fuentes A, Stertman L. Matrix-M \u2122 adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One. 2012;7:e41451.","journal-title":"PLoS One"},{"key":"535_CR24","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00262-006-0276-x","volume":"56","author":"S Jong de","year":"2007","unstructured":"de Jong S, Chikh G, Sekirov L, Raney S, Semple S, Klimuk S, et al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol Immunother. 2007;56:1251\u201364.","journal-title":"Cancer Immunol Immunother"},{"key":"535_CR25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1152\/physrev.00011.2010","volume":"91","author":"H Kettenmann","year":"2011","unstructured":"Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev. 2011;91:461\u2013553.","journal-title":"Physiol Rev"},{"key":"535_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/hmg\/ddp293","volume":"18","author":"YJ Crow","year":"2009","unstructured":"Crow YJ, Rehwinkel J. Aicardi-Gouti\u00e9res Syndrome and related phenotypes: Linking nucleic acid metabolism with autoimmunity. Hum Mol Genet. 2009;18:130\u20136.","journal-title":"Hum Mol Genet"},{"key":"535_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrneurol.2015.143","volume":"11","author":"S McGlasson","year":"2015","unstructured":"McGlasson S, Jury A, Jackson A, Hunt D. Type I interferon dysregulation and neurological disease. Nat Rev Neurol. 2015;11:515\u201323.","journal-title":"Nat Rev Neurol"},{"key":"535_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2217\/cns.14.41","volume":"3","author":"NU Barua","year":"2014","unstructured":"Barua NU, Gill SS. Convection-enhanced drug delivery: Prospects for glioblastoma treatment. CNS Oncol. 2014;3:313\u20136.","journal-title":"CNS Oncol"},{"key":"535_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","volume":"87","author":"MM Evers","year":"2015","unstructured":"Evers MM, Toonen LJ. van Roon-Mom WM. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev. 2015;87:90\u2013103.","journal-title":"Adv Drug Deliv Rev"},{"key":"535_CR30","first-page":"59","volume":"6","author":"AT Healy","year":"2015","unstructured":"Healy AT, Vogelbaum MA. Convection-enhanced drug delivery for gliomas. Surg Neurol Int. 2015;6:59\u201367.","journal-title":"Surg Neurol Int"},{"key":"535_CR31","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/neuonc\/nop054","volume":"12","author":"S Kunwar","year":"2010","unstructured":"Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010;12:871\u201381.","journal-title":"Neuro Oncol"},{"key":"535_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/10717544.2014.908248","volume":"23","author":"NU Barua","year":"2016","unstructured":"Barua NU, Hopkins K, Woolley M, O'Sullivan S, Harrison R, Edwards RJ, et al. A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma. Drug Deliv. 2016;23:167\u201373.","journal-title":"Drug Deliv"},{"key":"535_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3171\/2016.1.JNS151591","volume":"126","author":"A Jahangiri","year":"2017","unstructured":"Jahangiri A, Chin AT, Flanigan PM, Chen R, Bankiewicz K, Aghi MK. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg. 2017;126:191\u2013200.","journal-title":"J Neurosurg"},{"key":"535_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/neuonc\/nop047","volume":"12","author":"A Carpentier","year":"2010","unstructured":"Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barri\u00e9 M, et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol. 2010;12:401\u20138.","journal-title":"Neuro Oncol"},{"key":"535_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1215\/S1522851705000475","volume":"8","author":"A Carpentier","year":"2006","unstructured":"Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol. 2006;8:60\u20136.","journal-title":"Neuro Oncol"},{"key":"535_CR36","doi-asserted-by":"publisher","first-page":"14979","DOI":"10.1074\/jbc.M115.652156","volume":"12","author":"V Oganesyan","year":"2015","unstructured":"Oganesyan V, Peng L, Woods RM, Wu H, Dall'Acqua WF. Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab. J Biol Chem. 2015;12:14979\u201385.","journal-title":"J Biol Chem"},{"key":"535_CR37","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/art.37824","volume":"65","author":"M Petri","year":"2013","unstructured":"Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, et al. Sifalimumab, a human anti-interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013;65:1011\u201321.","journal-title":"Arthritis Rheum"},{"key":"535_CR38","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/ijc.29121","volume":"15","author":"D Vecchio","year":"2015","unstructured":"Vecchio D, Daga A, Carra E, Marubbi D, Raso A, Mascelli S, et al. Pharmacokinetics, pharmacodynamics and efficacy on pediatric tumors of the glioma radiosensitizer KU60019. Int J Cancer. 2015;15:1445\u201357.","journal-title":"Int J Cancer"},{"key":"535_CR39","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/sj.onc.1205179","volume":"14","author":"L Thyrell","year":"2002","unstructured":"Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002;14:1251\u201362.","journal-title":"Oncogene"},{"key":"535_CR40","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/glia.20272","volume":"53","author":"DL Herber","year":"2006","unstructured":"Herber DL, Maloney JL, Roth LM, Freeman MJ, Morgan D, Gordon MN. Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia. 2006;53:382\u201391.","journal-title":"Glia"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13346-018-0535-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-018-0535-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-018-0535-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T08:08:54Z","timestamp":1720339734000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13346-018-0535-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,4]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1007\/s13346-018-0535-3","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"type":"print","value":"2190-393X"},{"type":"electronic","value":"2190-3948"}],"subject":[],"published":{"date-parts":[[2018,6,4]]},"assertion":[{"value":"4 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"\u115f","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"All animal experiments were performed in compliance with international and national guidelines. The experimental proto<!--Too long, content removed-->"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}